[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-prostatic-hyperplasia-with-lower-urinary-tract-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-prostatic-hyperplasia-with-lower-urinary-tract-symptoms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,75,106,135,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635459","feasibility-and-utility-of-a-prehabilitation-program-for-use-in-patients-with-benign-prostatic-hyperplasia-who-have-elected-to-undergo-holmium-laser-enucleation-of-the-prostate-holep-100635459",false,"NCT07552961","Feasibility and Utility of a Prehabilitation Program for Use in Patients With Benign Prostatic Hyperplasia Who Have Elected to Undergo Holmium Laser Enucleation of the Prostate (HoLEP).","Evaluating the Feasibility of a Comprehensive Prehabilitation Program for Use in Benign Prostatic Hyperplasia Patients Undergoing Holmium Laser Enucleation of the Prostate","Inclusion Criteria:\n\n1. Opting to undergo HoLEP procedure for the treatment of BPH\n2. Estimated prostate size (\\>60 ml)\n3. Have received permission to exercise from their primary care provider\n4. Access to a computer\u002F smartphone and internet access to complete associated questionnaires and access online educational resource\n\nExclusion Criteria:\n\n1\\. Other medical or psychiatric conditions which preclude the ability to participate in exercise or utilize the online education module","MALE","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","Benign prostatic hyperplasia (BPH) is a debilitating condition which is highly prevalent in older males, up to 45% of those over the age of 45 are affected and 80% of those over the age of 70 are affected. While not all men with BPH experience problematic symptoms, many will experience lower urinary tract symptoms (LUTS) including difficulty passing urine, recurrent urinary tract infections, bladder stones, and hematuria. Holmium Laser Enucleation of the Prostate (HoLEP) is the gold standard in terms of surgical BPH management and is associated with a low risk for requiring repeat interventions. However, in the weeks following HoLEP procedures many men will experience transient urinary incontinence which can be distressing to patients.\n\nIn the setting of prostate cancer, exercise and mental health supports prior to surgery has been shown to improve incontinence and post-surgical recovery. This is often termed prehabilitation and consists of programming done in the months before surgery. The objective of this study is to assess the safety and feasibility of prehabilitation programming prior to HoLEP procedures for men with BPH.\n\nThe investigators will be randomizing 40 patients into 2 groups, one receiving standard of care interventions prior to their HoLEP surgery and one receiving at least 12 weeks of comprehensive prehabilitation programming including: pelvic floor physiotherapy, access to additional informational resources, and access to mental health supports including individual and couples counselling. In both groups the investigators will be collecting key demographics and clinical information from patients as well as assessing their urinary function through several questionnaires before prehabilitation, immediately before surgery, and up to 1 year after surgery.\n\nThe investigators hope to establish that prehabilitation is a safe and feasible option for these patients. Secondarily investigators hope to provide evidence that prehabilitation improves incontinence faster following HoLEP procedures and improves post-surgical recovery.",[26,27,28],"Benign Prostatic Hyperplasia","Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms","Benign Prostatic Hyperplasia With Outflow Obstruction",[30,31,32,33,34,35,36],"Prehabilitation","Exercise Therapy","Holmium Laser Enucleation of the Prostate","Mental Health Support","Safety","Feasibility","Incontinence","NOT_YET_RECRUITING","2026-04-22",{"date":40,"type":41},"2026-04-27","ACTUAL",{"date":43,"type":20},"2026-06-01",{"date":45,"type":20},"2027-11-01",{"name":47,"class":48},"University of Calgary","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100624945","comparison-between-water-vapor-thermal-therapy-and-prostatic-artery-embolization-in-treatment-of-benign-prostatic-hyperplasia-100624945","NCT07416227","Comparison Between Water Vapor Thermal Therapy and Prostatic Artery Embolization in Treatment of Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Age ≥50 years.\n* IPSS ≥13.\n* Prostate volume between 30-80 mL.\n* Maximum urinary flow rate (Qmax) ≤15 mL\u002Fsec in patients with voiding LUTs.\n* Patients not responding to medical treatment.\n\nExclusion Criteria:\n\n* History or suspicion of prostate cancer.\n* Previous prostate surgery or minimally invasive BPH intervention.\n* Neurological bladder dysfunction.\n* Active urinary tract infection.","50 Years",{"count":58,"type":20},30,[23],"The aim of this study is to compare the effectiveness of Rezum therapy versus Prostatic Artery Embolization in managing moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), with the primary endpoint being the improvement in the International Prostate Symptom Score (IPSS) over a 6-month follow-up period. Secondary endpoints include changes in post-void residual urine (PVR), maximum urinary flow rate (Qmax), patient-reported quality of life (QoL), and the preservation of ejaculatory and overall sexual function as assessed by validated questionnaires. This study aims to provide evidence-based guidance for optimizing treatment strategies for men with BPH, particularly those seeking alternatives to pharmacological therapy.",[27],[63,64],"Comparison between Water Vapor Thermal Therapy and Prostatic Artery Embolization in treatment of Benign Prostatic Hyperplasia","Rezum vs Prostatic artery embolization in the treatment of Benign prostatic hyperplasia with lower urinary tract symptoms","RECRUITING","2026-02-14",{"date":68,"type":41},"2026-02-18",{"date":70,"type":41},"2025-10-01",{"date":72,"type":20},"2027-10-01",{"name":74,"class":48},"Ain Shams University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100604197","phase-3-a-phase-iii-clinical-study-of-h077-sustained-release-tablets-compared-with-silodosin-capsules-in-the-treatment-of-benign-prostatic-hyperplasia-100604197","NCT07146386","A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia","A Randomized, Double-blind, Controlled, Non-inferiority Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of H077 Sustained-release Tablets Versus Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n1. Male, aged 50 to 75 years old, inclusive of both endpoints;\n2. Meets the clinical diagnostic criteria for benign prostatic hyperplasia (BPH);\n3. IPSS score was ≥ 8 points, and the QOL score was ≥ 3 points during the screening period;\n4. Prostate volume ≥ 20 ml (measured by transabdominal ultrasound);\n5. PSA≤4 ng\u002FmL;\n6. During the screening period, Qmax \\> 5 ml\u002Fs and Qmax \\\u003C15 ml\u002Fs (urine output ≥ 125 ml);\n7. The subjects had no intention of having children from the screening stage until 6 months after the last administration of the drug, and they were able to take effective contraceptive measures;\n8. Understand and voluntarily sign the written informed consent form (ICF), and be willing and capable of undergoing regular visits, treatment plans, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n1. Those who are allergic to any component of α\u002Fβ-adrenergic receptor blockers or the test drugs; or who have contraindications;\n2. History or evidence of prostate cancer (such as positive biopsy or ultrasound result, suspicious DRE findings), excluding patients who had suspicious ultrasound or DRE findings within 6 months prior to the screening but had negative biopsy results and stable PSA levels;\n3. During the screening process, researchers identified patients with BPH who required minimally invasive prostate treatment or surgical intervention;\n4. Has previously undergone prostate surgery, including open prostate surgery, transurethral minimally invasive prostate surgery, balloon dilation or stent replacement, or other invasive measures for treating BPH;\n5. Subjects with residual urine volume greater than 100 mL (measured by transabdominal ultrasound) or those for whom catheterization is deemed necessary by the investigator;\n6. Subjects who underwent cystoscopy, other transurethral endoscopic procedures, or therapeutic urinary catheterization within 1 month prior to the screening period;\n7. Subjects with a history of acute urinary retention (AUR) or cystostomy within 3 months prior to the screening period;\n8. Subjects with documented pelvic cavity trauma or urethral surgical interventions;\n9. During the screening period, any disease other than BPH that the investigator deems could cause urinary symptoms or changes in urine flow rate (such as neurogenic bladder, bladder neck fibrosis, bladder tumor, urinary calculi, urethral stricture, phimosis or penile tumor, acute or chronic prostatitis, acute or chronic urinary tract infection, acute or chronic renal failure, congenital developmental abnormalities of the urinary and reproductive system, etc.) must be excluded;\n10. During the screening period, subjects with positive hepatitis B surface antigen (HBsAg) and HBV-DNA levels greater than 500 IU\u002Fml, or with positive hepatitis C virus antibody (HCV-Ab) and HCV-RNA levels greater than 500 IU\u002Fml, or who had received hepatitis-related antiviral drug treatment within 6 months prior to the first administration;\n11. During screening period, the levels of aspartate transaminase (AST) or alanine transaminase (ALT) were more than 3 times the upper limit of the normal range;\n12. During the screening period, serum creatinine was greater than 1.5 times the upper limit of the normal range;\n13. Patients who plan to undergo cataract surgery during the medication period and within 3 months after the medication is completed;\n14. Currently or previously have the following diseases or conditions: a) Have a clear history of orthostatic hypotension in the past, or have a positive orthostatic hypotension test; or have a history of malignant hypertension; b) Have recurrent dizziness, vertigo, loss of consciousness or syncope, or any other signs or symptoms that the investigator considers may be worsened by celerodisonic; c) Have undergone major surgery (excluding biopsy) within 4 weeks before screening and have not fully recovered; d) Have had myocardial infarction, unstable angina pectoris, need for clinical intervention or clinical symptoms of arrhythmia, need for clinical intervention or clinical symptoms of congestive heart failure, or any cerebrovascular accident within 6 months before screening; e) Have a previous surgical history or have severe gastrointestinal diseases, which the investigator considers may affect the absorption, distribution, metabolism, etc. of the study drug; f) Have active infectious diseases and require systemic anti-infection treatment; g) Have a history of diabetes and poor blood sugar control, or have patients with diabetic nephropathy that require drug control; h) Have had malignant tumors within 5 years before screening; i) Have patients with other serious primary diseases and functional disorders in the heart, brain, lungs, liver, kidneys, hematopoietic system, endocrine system, etc;\n15. Currently or previously used the following drugs: a) Within 3 months before screening or during the study, need to use 5α-reductase inhibitors, anti-androgen drugs, and androgen drugs or any other drugs that affect hormone levels or prostate volume; b) Within 2 weeks before screening or during the study, need to use any α-adrenergic receptor blockers or any α-receptor blockers other than cilorodin during the study; c) Within 4 weeks before screening or during the study, need to use PDE-5 inhibitors, anticholinergic drugs, anticholinergic drugs or any other drugs that affect urinary function; d) Within 2 weeks before screening or during the study, need to use traditional Chinese medicine, Chinese herbs, or botanical preparations with indications for BPH; e) Within 4 weeks before screening or during the study, need to use any CYP3A4 strong inhibitors, CYP3A4 strong inducers or P-gp strong inhibitors;\n16. Subjects who participated in other drug or device clinical trials within 3 months prior to screening;\n17. Subjects with current alcohol or substance abuse were excluded;\n18. The researchers determined that the patient had other circumstances that affected the safety or efficacy assessment of the study drug, the obtaining of informed consent, or the compliance with the study procedures.","75 Years",{"count":84,"type":20},728,[86],"PHASE3","This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic hyperplasia.",[26,27],[90,91,92,93,94],"Benign prostatic hyperplasia","lower urinary tract symptoms","Silodosin","selective α1A-adrenergic receptor blocker","IPSS scores","2025-08-22",{"date":97,"type":41},"2025-08-28",{"date":99,"type":20},"2025-08",{"date":101,"type":20},"2027-03",{"name":103,"class":104},"Shanghai Huilun Pharmaceutical Co., Ltd.","INDUSTRY",66,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":49},"100591670","bipolar-resection-vs-enucleation-of-prostate-100591670","NCT06983444","Bipolar Resection vs Enucleation of Prostate","Bipolar Trans Urethral Resection of the Prostate (TURP) Versus Bipolar Enucleation of the Prostate in Treatment of Benign Prostatic Hyperplasia (BPH): A Prospective Randomized Comparative Clinical Study","TURP vs BiTUEP","Inclusion Criteria:\n\n1. Patients with lower urinary tract symptoms (LUTS) due to BPH.\n2. Patients with international prostate score system (IPSS) more than 8.\n3. Patients with maximal urinary flow rate (Qmax) less than 10ml\u002Fsecond.\n4. Patients with Prostatic volume (60 - 100 gm).\n5. Patient with indication for surgical intervention.\n6. Patient age (50-80 years old)\n\nExclusion Criteria:\n\n1. Prostatic cancer.\n2. Bladder cancer.\n3. Urethral stricture.\n4. Neurogenic bladder.","80 Years",{"count":116,"type":20},100,[23],"The aim of this study is to evaluate efficacy and safety of transurethral resection of the prostate and bipolar enucleation of the prostate.",[120,28,121,27],"Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection","Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms",[123,124,125],"TURP","TUEP","BPH","2025-05-17",{"date":128,"type":41},"2025-05-21",{"date":130,"type":20},"2025-06-01",{"date":132,"type":20},"2026-07",{"name":134,"class":48},"South Valley University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":49},"100558101","phase-3-efficacy-and-safety-of-two-fixed-dose-combinations-in-men-with-lower-urinary-tract-symptoms-associated-with-benign-prostatic-hyperplasia-benipro-100558101","NCT06546735","Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. (BENIPRO)","Randomized, Double-blind, Double-masked, Parallel-group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.","BENIPRO","Inclusion Criteria:\n\n* Ability to confirm voluntary participation and agree to all purposes of the trial by signing and dating the Informed Consent Form in two copies.\n* Men ≥40 years of age.\n* History of overactive bladder symptoms (urinary frequency and urgency with or without urinary incontinence) and LUTS for at least 3 months due to BPH.\n* History of urinary symptoms (≥1 urgency\u002F24-hour episode and ≥8 urination\u002F24-hour) for at least 3 months prior to screening.\n\nExclusion Criteria:\n\n* Participant who has received mirabegrone or antimuscarinics for the treatment of LUTS within the last 30 days prior to the Screening Visit.\n* Participant with evidence of lower urinary tract infection (UTI), confirmed by a culture \\>100,000 CFU\u002FmL. Should a participant present with a UTI at screening, they may be screened again after successful UTI treatment (confirmed by negative urine culture).\n* Participant with symptomatic UTI, prostatitis, or chronic inflammation (such as interstitial cystitis, bladder stones, prior pelvic radiation therapy, or previous or current malignancy within the boundaries of the pelvis, including bladder, prostate, and rectum).\n* History of recurrent UTI (2 episodes in the last 6 months or 3 episodes in the last year).\n* Participant who has neurogenic bladder (spinal cord injury, multiple sclerosis, Parkinson's, etc.).\n* Participant with a previous diagnosis of diabetic neuropathy.\n* History of previous open, robotic, or minimally invasive prostate surgery (including transurethral procedures), or reconstructive bladder surgery.\n* Participant with planned pelvic or prostate surgery during the trial period.\n* Participant with planned cataract or glaucoma surgery during the trial period.\n* Participant with significant stress incontinence or post-surgical prostate incontinence as determined by the Investigator.","40 Years",{"count":145,"type":20},816,[86],"The clinical trial to evaluate the fixed-dose combination (N0728), with the aim of providing the Brazilian market with an alternative, potentially effective, safe and convenient therapeutic approach for the treatment of Lower Urinary Tract Symptoms (LUTS) in men with Benign Prostatic Hyperplasia (BPH). The fixed-dose combination has synergistic action between drugs from different classes and offers significant potential advantages, such as better adherence to treatment. The trial will assess the non-inferiority in efficacy and safety of the proposed fixed-dose combination compared to alpha-adrenergic antagonists.",[149],"Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms","2024-11-13",{"date":152,"type":41},"2024-11-15",{"date":154,"type":20},"2026-11-30",{"date":156,"type":20},"2028-08-30",{"name":158,"class":104},"Eurofarma Laboratorios S.A.",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":167,"maxAge":114,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":170,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100481608","phase-4-the-efficacy-and-safety-of-silodosin-singly-or-combined-with-ningmitai-capsules-in-the-treatment-of-benign-prostatic-hyperplasia-100481608","NCT05551221","The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia","The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia (BPH) Complicated With Lower Urinary Tract Symptoms (LUTS) -A Multicenter, Prospective, Randomized, Double-blind, Positive Controlled Study","NQTIPS","Inclusion Criteria:\n\n1. Male Subjects aged 60 ～ 80 years, clinically diagnosed as benign prostatic hyperplasia.\n2. Has an IPSS score ≥ 8 points at Screening and Baseline.\n3. Has a 4 ≤ Qmax ≤ 15 ml\u002Fs when urination volume \\> 150 ml.\n4. Has a prostate volume (PV) ≥ 30 ml by ultrasound examination.\n5. Subjects who can read, understand, and complete the research questionnaire.\n6. Subjects willing to participate voluntarily in this clinical trial, give informed consent and sign informed consent.\n\nExclusion Criteria:\n\n1. Subjects with prostate cancer or other malignant tumors.\n2. Subjects have serum tPSA \\> 10ng\u002Fml, or 4 ≤ tPSA ≤ 10ng\u002Fml while fPSA\u002FtPSA \\\u003C 0.16 times.\n3. Subjects suffered from other diseases causing dysuria, such as bladder neck spasm, urethral stricture, neurogenic bladder dysfunction, etc.\n4. Subjects have suffered from acute urinary retention, or complicated with gross hematuria, urinary tract infection, bladder stones, secondary upper urinary tract hydronephrosis, urinary incontinence, renal insufficiency and other Subjects that researchers believe meet the surgical indications.\n5. Subjects have undergone prostate surgery, microwave therapy, urethral dilatation or acute urinary retention catheterization or other invasive procedures.\n6. Subjects have residual urine volume (PVR) \\> 100ml, or those who may have urinary retention and need catheterization.\n7. Subjects who took α receptor blockers, traditional Chinese medicine or botanical drugs for treating BPH within two weeks before participating this clinical trial.\n8. Subjects who take 5α reductase inhibitor or other antiandrogen therapy drugs within half a year before participating this clinical trial.\n9. Subjects who need to take drugs prohibited in this study or adopt prohibited treatment methods during treatment.\n10. Subjects who Complicated with severe cardiovascular and cerebrovascular diseases, respiratory diseases, blood diseases, liver and kidney diseases.\n11. There are significant abnormalities in clinical or laboratory examination indexes of patients, such as ALT and AST ≥ 2.5 times of the upper limit of reference value, creatinine (Scr) \\> 1.5 times of the upper limit of reference value, or poor blood glucose control (fasting blood glucose FPG ≥ 10 mmol\u002FL).\n12. Subjects who are allergic to the drugs or ingredients used in the test definitely.\n13. Any otherSubjects in the opinion of researchers is not suitable for inclusion.","60 Years",{"count":169,"type":20},312,[171],"PHASE4","Objective: To evaluate the efficacy and safety of Ningmitai Capsules and Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules.\n\nStudy design: A multicenter, prospective, randomized, double-blind, positive controlled clinical study.\n\nInterventions:\n\nGroup A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks.\n\nGroup B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.",[27],[175,176,92],"Benign Prostatic Hyperplasia Silodosin Capsules","Ningmitai Capsule","2022-09-21",{"date":179,"type":41},"2022-09-23",{"date":181,"type":41},"2022-07-18",{"date":183,"type":20},"2026-12-31",{"name":185,"class":104},"Xintian Pharmaceutical",8]